VYNE Therapeutics Reports Positive Phase 1a MAD Data for VYN202
VYNE Therapeutics Inc., a Delaware-based biopharmaceutical company, recently disclosed significant developments in its clinical trials concerning VYN202, a novel BD2-Selective BET Inhibitor. The company issued a press release on December 23, 2024, highlighting positive top-line Phase 1a MAD (Multiple Ascending Dose) data for the experimental compound. The Phase 1a trial results indicated that VYN202 exhibited […]
More Stories
Consolidated Lithium Metals (CVE:CLM) Hits New 12-Month Low – Here’s What Happened
Consolidated Lithium Metals Inc. (CVE:CLM – Get Free Report) reached a new 52-week low during trading on Monday . The...
GSTechnologies (LON:GST) Hits New 12-Month High – Still a Buy?
GSTechnologies Ltd. (LON:GST – Get Free Report)’s share price reached a new 52-week high on Monday . The company traded...
AGC (OTCMKTS:ASGLY) Hits New 12-Month Low – Here’s Why
AGC Inc. (OTCMKTS:ASGLY – Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock...
CMC Metals (CVE:CMB) Sets New 52-Week Low – Should You Sell?
CMC Metals Ltd. (CVE:CMB – Get Free Report) hit a new 52-week low on Wednesday . The company traded as...
Vistry Group (LON:VTY) Stock Price Down 16.1% – Should You Sell?
Vistry Group PLC (LON:VTY – Get Free Report)’s share price dropped 16.1% during mid-day trading on Wednesday . The stock...
Versarien (LON:VRS) Trading Up 3.4% – Here’s Why
Versarien plc (LON:VRS – Get Free Report) shares traded up 3.4% on Monday . The stock traded as high as...